• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Covid-19:肾素-血管紧张素系统失衡假说。

Covid-19: the renin-angiotensin system imbalance hypothesis.

机构信息

Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.

出版信息

Clin Sci (Lond). 2020 Jun 12;134(11):1259-1264. doi: 10.1042/CS20200492.

DOI:10.1042/CS20200492
PMID:32507883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7276636/
Abstract

The emergency of SARS-CoV-2 in China started a novel challenge to the scientific community. As the virus turns pandemic, scientists try to map the cellular mechanisms and pathways of SARS-CoV-2 related to the pathogenesis of Coronavirus Disease 2019 (Covid-19). After transmembrane angiotensin-converting enzyme 2 (ACE2) has been found to be SARS-CoV-2 receptor, we hypothesized an immune-hematological mechanism for Covid-19 based on renin-angiotensin system (RAS) imbalance to explain clinical, laboratory and imaging findings on disease course. We believe that exaggerated activation of ACE/Angiotensin II (Ang II)/Angiotensin Type 1 (AT1) receptor RAS axis in line with reduction of ACE2/Angiotensin-(1-7)/Mas receptor may exert a pivotal role in the pathogenesis of Covid-19. In this perspective, we discuss potential mechanisms and evidence on this hypothesis.

摘要

新型冠状病毒在中国的爆发给科学界带来了新的挑战。随着病毒的流行,科学家们试图描绘与 2019 年冠状病毒病(Covid-19)发病机制相关的 SARS-CoV-2 的细胞机制和途径。在发现跨膜血管紧张素转换酶 2(ACE2)是 SARS-CoV-2 的受体后,我们基于肾素-血管紧张素系统(RAS)失衡假设了一种免疫血液学机制来解释疾病过程中的临床、实验室和影像学发现。我们认为,ACE/血管紧张素 II(Ang II)/血管紧张素 1 型(AT1)受体 RAS 轴的过度激活以及 ACE2/血管紧张素(1-7)/Mas 受体的减少可能在 Covid-19 的发病机制中发挥关键作用。在这篇观点文章中,我们讨论了这一假设的潜在机制和证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc30/7276636/46c8e7fc57b7/cs-134-cs20200492-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc30/7276636/1c5d8b7163c4/cs-134-cs20200492-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc30/7276636/46c8e7fc57b7/cs-134-cs20200492-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc30/7276636/1c5d8b7163c4/cs-134-cs20200492-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc30/7276636/46c8e7fc57b7/cs-134-cs20200492-g2.jpg

相似文献

1
Covid-19: the renin-angiotensin system imbalance hypothesis.Covid-19:肾素-血管紧张素系统失衡假说。
Clin Sci (Lond). 2020 Jun 12;134(11):1259-1264. doi: 10.1042/CS20200492.
2
Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).新型冠状病毒病 2019(COVID-19)与肾素-血管紧张素系统:深入了解血管紧张素转换酶 2(ACE2)。
Ann Clin Biochem. 2020 Sep;57(5):339-350. doi: 10.1177/0004563220928361. Epub 2020 Jun 2.
3
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.SARS-CoV-2 大流行和研究空白:了解 SARS-CoV-2 与 ACE2 受体的相互作用及其对治疗的影响。
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
4
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.新型冠状病毒相关肺损伤中经典肾素-血管紧张素系统与其拮抗系统之间的失衡。
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L325-L336. doi: 10.1152/ajplung.00189.2020. Epub 2020 Jul 8.
5
COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?新型冠状病毒肺炎与肾素-血管紧张素系统抑制:血管紧张素转换酶 2(ACE2)的作用-争议有何科学依据?
J Intern Med. 2020 Oct;288(4):410-421. doi: 10.1111/joim.13101. Epub 2020 Jun 8.
6
Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.ACE2 的发现与特性鉴定——从血管紧张素转化酶到 2020 年冠状病毒病的 20 年探索之旅。
Clin Sci (Lond). 2020 Sep 30;134(18):2489-2501. doi: 10.1042/CS20200476.
7
Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.用血管紧张素 AT2 受体激动剂纠正 COVID-19 中失衡的保护性 RAS。
Clin Sci (Lond). 2020 Nov 27;134(22):2987-3006. doi: 10.1042/CS20200922.
8
A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.维生素 D 与血管紧张素转换酶 2 相互作用的简要综述:COVID-19 潜在治疗方法的启示。
Rev Med Virol. 2020 Sep;30(5):e2119. doi: 10.1002/rmv.2119. Epub 2020 Jun 25.
9
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行:目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
10
ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.ACE2(血管紧张素转化酶 2)、COVID-19 以及大流行期间 ACE 抑制剂和血管紧张素 II(血管紧张素 II)受体阻滞剂的使用:儿科观点。
Hypertension. 2020 Jul;76(1):16-22. doi: 10.1161/HYPERTENSIONAHA.120.15291. Epub 2020 May 5.

引用本文的文献

1
Infection to hypertension: a review of post-COVID-19 new-onset hypertension prevalence and potential underlying mechanisms.感染与高血压:COVID-19后新发高血压患病率及潜在机制综述
Front Cardiovasc Med. 2025 Aug 18;12:1609768. doi: 10.3389/fcvm.2025.1609768. eCollection 2025.
2
Post-COVID Hypertension With Hyperreninemic Hyperaldosteronism in a Pediatric Patient.一名儿科患者的新冠后高血压伴高肾素性醛固酮增多症
Clin Case Rep. 2025 Jan 14;13(1):e70119. doi: 10.1002/ccr3.70119. eCollection 2025 Jan.
3
JN. 1 and cardiac-related clinical manifestations: a current public health concern.

本文引用的文献

1
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion.撤回说明:严重急性呼吸综合征冠状病毒2通过其刺突蛋白介导的膜融合感染T淋巴细胞。
Cell Mol Immunol. 2020 Aug;17(8):894. doi: 10.1038/s41423-020-0498-4.
2
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality.COVID-19 患者的性别差异:关注严重程度和死亡率。
Front Public Health. 2020 Apr 29;8:152. doi: 10.3389/fpubh.2020.00152. eCollection 2020.
3
Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.
JN.1与心脏相关临床表现:当前的公共卫生问题
Front Cardiovasc Med. 2024 Dec 9;11:1488226. doi: 10.3389/fcvm.2024.1488226. eCollection 2024.
4
Type 2 Diabetes Mellitus Aggravates Complement Dysregulation and Affects Cortisol Response in Patients with Post-COVID-19.2型糖尿病会加重新冠后患者的补体失调并影响皮质醇反应。
Diabetes Metab Syndr Obes. 2024 Oct 19;17:3849-3861. doi: 10.2147/DMSO.S480457. eCollection 2024.
5
Association of COVID-19 infection and the risk of new incident diabetes: a systematic review and meta-analysis.新型冠状病毒感染与新发糖尿病风险的关联:系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2024 Aug 26;15:1429848. doi: 10.3389/fendo.2024.1429848. eCollection 2024.
6
Assessing the impact of COVID-19 on acute leukemia patients: a comparative analysis of hematological and biochemical parameters.评估 COVID-19 对急性白血病患者的影响:血液学和生化学参数的对比分析。
BMC Infect Dis. 2024 Jun 11;24(1):576. doi: 10.1186/s12879-024-09485-9.
7
Covid-19, leukemia, and secondary malignancies of the skin - is there a connection: a case report and literature analysis.新型冠状病毒肺炎、白血病与皮肤继发性恶性肿瘤——它们之间有关联吗:一例病例报告及文献分析
Front Oncol. 2023 Oct 27;13:1265479. doi: 10.3389/fonc.2023.1265479. eCollection 2023.
8
Risk factors for death in hospitalized COVID-19 patients in Africa: A systematic review and meta-analysis.非洲住院 COVID-19 患者死亡的风险因素:系统评价和荟萃分析。
Medicine (Baltimore). 2023 Sep 1;102(35):e34405. doi: 10.1097/MD.0000000000034405.
9
The Effect of COVID-19 Severity, Associated Serum Autoantibodies and Time Interval after the Disease on the Outcomes of Fresh Oocyte ART Cycles in Non-Vaccinated Patients.2019冠状病毒病严重程度、相关血清自身抗体及患病后时间间隔对未接种疫苗患者新鲜卵母细胞辅助生殖技术周期结局的影响
J Clin Med. 2023 Jun 29;12(13):4370. doi: 10.3390/jcm12134370.
10
Angiotensin-Converting Enzyme (ACE) level, but not ACE gene polymorphism, is associated with prognosis of COVID-19 infection: Implications for diabetes and hypertension.血管紧张素转化酶(ACE)水平,而不是 ACE 基因多态性,与 COVID-19 感染的预后相关:对糖尿病和高血压的影响。
PLoS One. 2023 Jul 11;18(7):e0288338. doi: 10.1371/journal.pone.0288338. eCollection 2023.
高血压、血栓形成、肾衰竭与糖尿病:新型冠状病毒肺炎是一种内皮疾病吗?临床及基础证据的综合评估
J Clin Med. 2020 May 11;9(5):1417. doi: 10.3390/jcm9051417.
4
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下:一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
5
Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study.伊朗 2019 冠状病毒病(COVID-19)患者的流行病学特征:一项单中心研究。
J Clin Virol. 2020 Jun;127:104378. doi: 10.1016/j.jcv.2020.104378. Epub 2020 Apr 21.
6
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.利用人血管紧张素转化酶 2 进入 SARS-CoV-2 的结构和功能基础
Cell. 2020 May 14;181(4):894-904.e9. doi: 10.1016/j.cell.2020.03.045. Epub 2020 Apr 9.
7
ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19.ACE2 两面蛋白——从心血管保护到严重急性呼吸综合征冠状病毒 2 和 COVID-19。
Clin Sci (Lond). 2020 Apr 17;134(7):747-750. doi: 10.1042/CS20200363.
8
The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science.2019冠状病毒病、衰老与心血管疾病的困境:心血管衰老科学的见解
JAMA Cardiol. 2020 Jul 1;5(7):747-748. doi: 10.1001/jamacardio.2020.1329.
9
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.2019冠状病毒病(COVID-19)与心血管疾病:关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的发病和严重程度潜在影响的观点
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.
10
Reply to: 'Interaction between RAAS inhibitors and ACE2 in the context of COVID-19'.回复:“2019冠状病毒病背景下肾素-血管紧张素-醛固酮系统抑制剂与血管紧张素转换酶2的相互作用”
Nat Rev Cardiol. 2020 May;17(5):313-314. doi: 10.1038/s41569-020-0369-9.